Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 61-69

  Helm, Cyril William ^a   Richard, Scott D ^b   Pan, Jianmin ^c   Bartlett, David ^d   Goodman, Martin D ^e   Hoefer, Rick ^f   Lentz, Sam S ^g   Levine, Edward A ^g   Loggie, Brian W ^h   Metzinger, Daniel S ^a   Miller, Brigitte ^g   Parker, Lynn ^a   Spellman, James E ⁱ   Sugarbaker, Paul H ^j   Edwards, Robert P ^b   Rai, Shesh N ^a,c  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f Surgical Oncology Newport News   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Beebe Medical Center   (United States)

^j WASHINGTON HOSPITAL CENTER   (United States)

more..

Author keywords

Cytoreductive surgery; Hyperthermia; Hyperthermic intraperitoneal chemotherapy (HIPEC); Intraperitoneal chemotherapy; Ovarian neoplasms

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; MITOMYCIN; OXALIPLATIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DYING; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; INFORMATION PROCESSING; INTERNET; LIFE EXTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM; SEPSIS; TEMPERATURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; REGISTRIES; SURVIVAL ANALYSIS; TEMPERATURE; YOUNG ADULT;

EID: 74249089375     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c50cde     Document Type: Article

References (53)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Canc J Clin. 2005;55:74-108.
2. Dedrick RI, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Canc Treat Rep. 1978;62:1-11.
3. Markman M. Intraperitoneal chemotherapy in the management of malignant disease. Exp Rev Anticanc Ther. 2001;1:142-148.
4. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [see comment]. N Eng J Med. 1996;335: 1950-1955.
5. Armstrong DK, Bundy BN, Wenzel L, et al; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Eng J Med. 2006;354:34-43.
6. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group [see comment]. J Clin Oncol. 2001;19:1001-1007.
7. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Coch Data Syst Rev. 2006;CD005340.
8. National Cancer Institute. NCI clinical announcement on intraperitoneal therapy for ovarian cancer. Available at: http://www.cancer.gov/clinicaltrials/ developments/IPchemo-digest. Accessed July 8, 2009.
9. Giovanella BC, Stehlin JS Jr, Morgan AC. Selective lethal effect of supranormal temperatures on human neoplastic cells. Canc Res. 1976;36:3944-3950.
10. Alberts DS, Peng YM, Chen HS, et al. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Canc Inst. 1980;65:455-461.
11. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Canc Res. 1980;40:1165-1168. (Pubitemid 10135826)
12. Wang BS, Lumanglas AL, Silva J, et al. Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone. Canc Treat Rep. 1987;71:831-836.
13. Xu MJ, Alberts DS. Potentiation of platinum analogue cytotoxicity by hyperthermia. Canc Chemother Pharmacol. 1988;21:191-196.
14. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Brit J Canc. 1994;69:235-241.
15. Maymon R, Bar-Shira Maymon B, Holzinger M, et al. Augmentative effects of intracellular chemotherapy penetration combined with hyperthermia in human ovarian cancer cells lines. Gynecol Oncol. 1994;55:265-270.
16. Haveman J, Rietbroek RC, Geerdink A, et al. Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer. 1995;62:627-630.
17. Rietbroek RC, van de Vaart PJ, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinumYDNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Canc Res Clin Oncol. 1997;123:6-12.
18. Hermisson M, Weller M. Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res. 2000;20:1819-1823. (Pubitemid 30628207)
19. Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hypertherm. 2002;18: 307-315.
20. Mohamed F, Marchettini P, Stuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463-468.
21. Takemoto M, Kuroda M, Urano M, et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hypertherm. 2003;19:193-203.
22. de Bree E, Theodoropoulos PA, Rosing H, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev. 2006;32:471-482.
23. Istomin YP, Zhavrid EA, Alexandrova EN, et al. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol. 2008;30:56-59.
24. Meyn RE, Corry PM, Fletcher SE, et al. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res. 1980;40:1136-1139.
25. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatinYDNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148-154.
26. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-260.
27. Spratt JS, Adcock RA, Sherrill W, et al. Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980; 40:253-255.
28. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer. 1997;79:884-891.
29. Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999-1003.
30. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727-731.
31. Helm CW, Toler CR, Martin RS III, et al. Surgical cytoreduction and intraperitoneal heated chemotherapy (IPHC) for endometrial carcinoma recurrent within the peritoneal cavity. Int J Gynecol Cancer. 2007;17:204-209.
32. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979-984.
33. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. [see comment]. Ann Surg Oncol. 2008;15:2426-2432.
34. Helm CW, Bristow RE, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. Journal of Surgical Oncology. 2008;98:283-290.
35. Oxford-Center for Evidence Based Medicine. http://www.cebm.net/levels-of- evidence.asp. Accessed March 11, 2009.
36. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49-58.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Assoc. 1958;53:457-481.
38. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Second Edition ed. New York: Wiley and Sons; 2002.
39. Cox DR. Regression models and life tables. Journal of the Royal Statist Soc. 1972;34:187-220.
40. Bereder J, Glehen O, Habre J. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: A multi-institutional study of 246 patients. Journal of Clinical Oncology. 2009;27:Abstr 5542.
41. Loggie BW, Sterchi JM, Rogers AT, et al. Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. Reg Cancer Treat. 1994;2:78-81.
42. Steller MA, Egorin MJ, Trimble EL, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.[erratum appears in Cancer Chemother Pharmacol. 1999;44(1):90]. Cancer Chemotherapy & Pharmacology. 1999;43:106-114.
43. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004;14:35-41.
44. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95:273-280.
45. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112: 265-274.
46. Gore ME, Fryatt I, Wiltshaw E, et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. Brit J Cancer. 1989;60:767-769.
47. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-393.
48. Helm CW, Randall-Whitis L, Martin RS, III, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 2007;105:90-96.
49. Deraco M, Rossi CR, Pennacchioli E, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori. 2001;87:120-126.
50. Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004;28: 1040-1045.
51. Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. [see comment]. World J Surg. 2007;31: 1813-1820.
52. Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006;94:316-324.
53. Reichman TW, Cracchiolo B, Sama J, et al. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol. 2005;90:51-56.